

Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in *Staphylococcus aureus* bacteraemia

J. H. HAN^{1*}, W. B. BILKER^{2,3}, P. H. EDELSTEIN⁴, K. B. MASCITTI⁵
AND E. LAUTENBACH^{1,2,3}

¹ Division of Infectious Diseases, Department of Medicine, ² Department of Biostatistics and Epidemiology,

³ Center for Clinical Epidemiology and Biostatistics, ⁴ Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

⁵ Division of Infectious Diseases, Department of Medicine St. Luke's Hospital and Health Network, Bethlehem, PA, USA

Received 18 December 2011; Final Revision 2 February 2012; Accepted 7 February 2012;
first published online 10 April 2012

SUMMARY

Reduced vancomycin susceptibility (RVS) may lead to poor clinical outcomes in *Staphylococcus aureus* bacteraemia. We conducted a cohort study of 392 patients with *S. aureus* bacteraemia within a university health system. The association between RVS, as defined by both Etest [vancomycin minimum inhibitory concentration (MIC) > 1.0 µg/ml] and broth microdilution (vancomycin MIC ≥ 1.0 µg/ml), and patient and clinical variables were evaluated to create separate predictive models for RVS. In total, 134 (34.2%) and 73 (18.6%) patients had *S. aureus* isolates with RVS by Etest and broth microdilution, respectively. The final model for RVS by Etest included methicillin resistance [odds ratio (OR) 1.51, 95% confidence interval (CI) 0.97–2.34], non-white race (OR 0.67, 95% CI 0.42–1.07), healthcare-associated infection (OR 0.56, 95% CI 0.32–0.96), and receipt of any antimicrobial therapy ≤ 30 days prior to the culture date (OR 3.06, 95% CI 1.72–5.44). The final model for RVS by broth microdilution included methicillin resistance (OR 2.45, 95% CI 1.42–4.24), admission through the emergency department (OR 0.54, 95% CI 0.32–0.92), presence of an intravascular device (OR 2.24, 95% CI 1.30–3.86), and malignancy (OR 0.51, 95% CI 0.26–1.00). The availability of an easy and rapid clinical prediction rule for early identification of RVS can be used to help guide the timely and individualized management of these serious infections.

Key words: Hospital-acquired (nosocomial) infections, infectious disease epidemiology, methicillin-resistant *S. aureus* (MRSA), *Staphylococcus aureus*.

INTRODUCTION

Staphylococcus aureus is a leading cause of infections in the USA and is associated with substantial morbidity and mortality [1–3]. Vancomycin has traditionally

been the mainstay of therapy for infections due to methicillin-resistant *S. aureus* (MRSA) as well as methicillin-susceptible *S. aureus* (MSSA) in patients unable to tolerate β-lactam antibiotics. However, recent evidence has emerged demonstrating a trend of increasing vancomycin minimum inhibitory concentrations (MICs) in vancomycin-susceptible *S. aureus* isolates, referred to as vancomycin ‘MIC creep’ [4–7].

Several studies suggest that infections caused by both MSSA and MRSA isolates with reduced

* Author for correspondence: J. H. Han, M.D., Division of Infectious Diseases, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor, Silverstein Building, Ste E, Philadelphia, PA 19104, USA.
(Email: jennifer.han@uphs.upenn.edu)

vancomycin susceptibility (RVS), as determined by Etest or broth microdilution methods [8, 9], are associated with higher rates of treatment failure and mortality, particularly in serious infections such as bacteraemia [10–21]. As such, a clinical prediction rule for RVS would have important implications for the clinical management of *S. aureus* bacteraemia, both for early recognition of a higher risk of treatment failure in these patients, as well as selection of antimicrobial therapy. To our knowledge, there is only one published study in the literature of a clinical prediction rule for RVS in bacteraemia due to *S. aureus* [22], but this was limited to MRSA isolates. Moreover, this study utilized broth microdilution susceptibility testing, which produces vancomycin MIC results that are consistently lower than those reported by Etest [23–25]. We conducted the present study in order to develop and validate clinical prediction rules for identifying RVS as determined by both Etest and broth microdilution testing in bacteraemia due to MSSA and MRSA.

METHODS

Study design and setting

This retrospective cohort study was conducted at two hospitals in the University of Pennsylvania Health System (UPHS) in Philadelphia: the Hospital of the University of Pennsylvania (HUP), a 725-bed academic tertiary-care medical centre, and Penn Presbyterian Medical Center (PPMC), a 344-bed urban community hospital. The study was approved by the institutional review board of the University of Pennsylvania.

Study population

All inpatients with an episode of *S. aureus* bacteraemia occurring between 1 December 2007 and 31 May 2009 were identified through the HUP Clinical Microbiology Laboratory, which processes all specimens obtained from patients at HUP and PPMC. For patients with multiple episodes of *S. aureus* bacteraemia, only the first episode of bacteraemia was included for analysis.

Microbiological identification and susceptibility testing of *S. aureus* isolates

Identification and susceptibility testing of *S. aureus* was performed and interpreted according to standard

methods [26–28]. Standard susceptibility testing was performed using the Vitek2 instrument method. For the purposes of this study, the vancomycin MIC of the isolates was determined by the Etest using Mueller–Hinton agar (BBL; BD Diagnostic Systems, USA) [8], with RVS defined as a vancomycin MIC $> 1.0 \mu\text{g/ml}$ [19]. In addition, vancomycin MICs were determined for all *S. aureus* isolates by the broth microdilution method [9], utilizing a susceptibility panel containing half-dilution vancomycin concentrations, custom manufactured by Trek Diagnostic Systems (USA), with RVS defined as a vancomycin MIC $\geq 1.0 \mu\text{g/ml}$ [12].

Data collection

Data were abstracted from the Pennsylvania Integrated Clinical and Administrative Research Database (PICARD), which includes demographic, laboratory, pharmacy, and billing information, and has been used effectively in prior studies of antibiotic use and resistance [28–30]. The following clinical data were collected for all subjects: baseline demographics, origin at the time of hospital admission (i.e. physician referral, transfer from another facility, or admission through the emergency department), healthcare-associated infection (transfer from another institution or date of the first positive culture ≥ 48 h from admission), hospital location at the time of infection [i.e. intensive care unit (ICU) or medical floor], prior admission to UPHS in the 30 days prior to the culture date, and the all patient refined-diagnosis related group (APRDRG) risk of mortality and severity of illness scores. The presence of the following comorbid conditions was documented in relation to the date of the positive blood culture: diabetes mellitus, malignancy, renal insufficiency (creatinine ≥ 2.0 mg/dl or the requirement of dialysis), solid organ or haematopoietic stem cell transplantation, HIV infection, neutropenia (absolute neutrophil count $< 500/\text{mm}^3$), and receipt of an immunosuppressive agent, including corticosteroids, in the previous 30 days. Furthermore, chart review was performed to collect data on the presence of complicated infection (i.e. endocarditis, osteomyelitis, septic arthritis, epidural and/or spinal abscess) and the presence of intravascular devices (i.e. intravascular catheter, pacemaker or defibrillator, arteriovenous fistula or graft) prior to the episode of bacteraemia. In addition, the Charlson comorbidity index was calculated for each subject [31].

All inpatient antimicrobial therapy administered during the 30 days prior to the episode of bacteraemia was documented. Antimicrobial therapy was categorized by agent or class, including vancomycin, aminoglycosides, extended-spectrum penicillins (e.g. piperacillin-tazobactam), other penicillins (e.g. penicillin, ampicillin, nafcillin, ampicillin/sulbactam), extended-spectrum cephalosporins (e.g. ceftriaxone, cefotaxime, cefepime), other cephalosporins (e.g. cefazolin), trimethoprim-sulfamethoxazole, fluoroquinolones, macrolides (e.g. azithromycin, erythromycin), tetracyclines (e.g. doxycycline), clindamycin, and metronidazole.

Statistical analysis

Model derivation

Models were derived separately for RVS as defined by (1) Etest and (2) broth microdilution testing. Bivariable analyses were conducted to determine the unadjusted association between RVS and potential predictors. Continuous variables were compared using Student's *t* test or Wilcoxon rank-sum test and categorical variables were compared using χ^2 test or Fisher's exact test. Multiple logistic regression analyses were subsequently performed, with variables with *P* values <0.20 on bivariable analyses considered for inclusion in the model [32]. Variables with a *P* value of <0.05 in a backward elimination process were retained in the final model. To double check that no significantly predictive variables were removed during this process, each de-selected variable was tested in turn with the final model and re-introduced into the model if the *P* value was <0.05. Furthermore, variables with a *P* value of <0.10 were retained based on the ability of the final model to predict the outcome of interest, as well as the ease of use and availability of the predictor on a clinical basis.

The final regression model was transformed to a simplified integer-based score, with a score for each predictor variable assigned by dividing its β -coefficient by the absolute value of the smallest coefficient in the model and rounding up to the nearest integer. The simplified model was built by including a summation of scores from the presence of all independent predictor variables as a single continuous variable.

Model performance characteristics

The sensitivity, specificity, negative predictive value, and positive predictive value for all possible cut-off

values were calculated for the final integer-based score model. The discriminatory ability of the prediction rule in the derivation group was quantified using the C statistic, or the area under the receiver-operating characteristic curve (AUC). Calibration was assessed using the Hosmer–Lemeshow χ^2 goodness-of-fit test [33], which evaluates expected and observed probabilities in population deciles. Over-optimism of the prediction characteristics refers to inflated predictive capability due to the model-fitting data typically performing better than data not used for the model-fitting process. In order to adjust for the over-optimism, a bootstrapping procedure for 'optimism' adjustment [34–36] was applied, based on 10 000 bootstraps. This procedure was used to calculate the optimism-adjusted C statistic for both the final model with all independent predictors, as well as the simplified model with the total score as the single predictor.

Model validation

The prediction rule was validated internally using the bootstrap method for over-optimism in the original derivation population [35, 36], with calculation of the C statistic as in the derivation process.

A two-tailed *P* value of <0.05 was considered significant. All statistical calculations were performed using commercially available software (Stata version 11.0; StataCorp LP, USA).

RESULTS

Study population

A total of 392 patients with discrete episodes of *S. aureus* bacteraemia were identified during the study period. There was a significant, although weak, correlation between vancomycin Etest MICs and vancomycin broth microdilution MICs (Spearman's correlation = 0.40, *P* < 0.001).

The distribution of vancomycin MICs among isolates as determined by Etest was as follows: 17 (4.3%) with MIC \leq 0.5 μ g/ml, 83 (21.2%) with MIC = 0.75 μ g/ml, 158 (40.3%) with MIC = 1.0 μ g/ml, 123 (31.4%) with MIC = 1.5 μ g/ml, and 11 (2.8%) with MIC = 2.0 μ g/ml [37]. Accordingly, 34.2% of the *S. aureus* bloodstream isolates demonstrated RVS as defined by a vancomycin MIC > 1.0 μ g/ml by Etest. The distribution of vancomycin MICs among isolates as determined by broth microdilution testing was as follows: one (0.3%) with MIC = 0.25 μ g/ml,

78 (19.9%) with MIC = 0.5 µg/ml, 240 (61.2%) with MIC = 0.75 µg/ml, 62 (15.8%) with MIC = 1.0 µg/ml, and 11 (2.8%) with MIC = 1.5 µg/ml. Accordingly, 73 (18.6%) had RVS as defined by a broth microdilution MIC \geq 1.0 µg/ml.

Derivation of the prediction rules

RVS defined by Etest

Significant univariable predictors of RVS as defined by Etest are shown in Table 1*a*. Isolates with RVS were significantly more likely to be methicillin resistant ($P=0.02$) and associated with bacteraemia in patients who had received antibiotics in the 30 days preceding the culture date ($P<0.001$), including an aminoglycoside ($P=0.04$) or a fluoroquinolone ($P=0.003$). The multivariable prediction model, including regression coefficients, adjusted odds ratios (ORs), and assigned point value for the integer-base score, is shown in Table 2*a*. The final model incorporated four independent predictors of RVS: methicillin resistance, non-white race, healthcare-associated infection, and receipt of any antimicrobial therapy \leq 30 days prior to the first positive blood culture date. A total score in the simplified model is therefore calculated by summation of individual point values of all predictors that are present for a given patient, with possible scores ranging from -2 to 4.

RVS defined by broth microdilution test

Significant univariable predictors of RVS as defined by broth microdilution testing are shown in Table 1*b*. Isolates with RVS were significantly more likely to be methicillin resistant ($P=0.001$) and healthcare-associated ($P=0.04$), as well as associated with bacteraemia in patients who were admitted through the emergency department ($P=0.01$), had an intravascular device ($P=0.01$), and were in the ICU at the time of or \leq 48 h prior to the first positive blood culture date ($P=0.01$ and $P=0.07$, respectively). The multivariable prediction model, including regression coefficients, adjusted ORs, and assigned point value for the integer-base score, is shown in Table 2*b*. The final model incorporated four independent predictors of RVS: methicillin resistance, admission through the emergency department, presence of an intravascular device, and malignancy. A total score is calculated in the same fashion as described for RVS as defined by Etest, with possible scores ranging from -2 to 2.

Discrimination, calibration, and validation

RVS defined by Etest

The clinical prediction rule for RVS as determined by Etest with four independent predictors demonstrated good discrimination (C statistic = 0.642, optimism-adjusted C statistic = 0.625) and was well-calibrated (Hosmer–Lemeshow $\chi^2=8.97$, $P=0.25$). When the prediction rule was applied to the validation cohort, the C statistic was 0.650. No collinear relationships were detected in the final model, with variation inflation factors for the variables ranging from 1.03–1.39.

The point-based prediction rule with total score as the single predictor also demonstrated good discrimination (C statistic = 0.646, optimism-adjusted C statistic = 0.645) and good calibration (Hosmer–Lemeshow $\chi^2=2.77$, $P=0.60$). Performance characteristics of the simplified prediction model are shown in Table 3. At the cut-off value of ≥ 0 , the clinical prediction rule demonstrated a sensitivity of 78.4% and a specificity of 42.6%. Similarly, at the cut-off value of ≥ 1 , the clinical prediction rule demonstrated a sensitivity of 47.8% and a specificity of 73.3%.

RVS defined by broth microdilution test

The clinical prediction rule for RVS as defined by broth microdilution test with four independent predictors demonstrated good discrimination (C statistic = 0.693, optimism-adjusted C statistic = 0.676) and was well-calibrated (Hosmer–Lemeshow $\chi^2=10.9$, $P=0.15$). When the prediction rule was applied to the validation cohort, the C statistic was 0.701. No collinear relationships were detected in the final model, with variation inflation factors for the variables ranging from 1.03 to 1.05.

The point-based prediction rule with total score as the single predictor also demonstrated good discrimination (C statistic = 0.684, optimism-adjusted C statistic = 0.683) and good calibration (Hosmer–Lemeshow $\chi^2=2.25$, $P=0.32$). Performance characteristics of the simplified prediction model are shown in Table 4. At the cut-off value of ≥ 0 , the clinical prediction rule demonstrated a sensitivity of 89.0% and a specificity of 27.0%. Similarly, at the cut-off value of ≥ 1 , the clinical prediction rule demonstrated a sensitivity of 61.6% and a specificity of 71.2%.

DISCUSSION

The results of our study suggest that a simplified, integer-based scoring model that uses readily available

Table 1. *Unadjusted variables associated with RVS as defined by (a) Etest and (b) broth microdilution test in Staphylococcus aureus bacteraemia*

Variable	No. (%) with RVS	No. (%) without RVS	<i>P</i> value	OR (95% CI)
(a) Etest	(<i>n</i> = 134)	(<i>n</i> = 258)		
Non-white race	56 (43.4)	129 (51.8)	0.12	0.71 (0.45–1.12)
Methicillin resistant isolate	76 (56.7)	114 (44.2)	0.02	1.66 (1.06–2.58)
Intravascular device	72 (53.7)	111 (43.2)	0.05	1.53 (0.98–2.38)
Diabetes mellitus	36 (26.9)	84 (32.6)	0.25	0.76 (0.46–1.24)
Malignancy	29 (21.6)	71 (27.5)	0.21	0.73 (0.43–1.22)
ICU location \leq 48 h prior to culture date	23 (17.2)	27 (10.5)	0.06	1.77 (0.92–3.37)
Inpatient antimicrobial use \leq 30 days prior to culture date*				
Any antibiotic	46 (34.3)	45 (17.4)	<0.001	2.47 (1.49–4.11)
Vancomycin	19 (14.2)	19 (7.4)	0.05	2.08 (1.00–4.32)
Aminoglycoside	10 (7.3)	7 (2.7)	0.04	2.89 (0.96–9.15)
Extended-spectrum cephalosporin	12 (9.0)	12 (4.7)	0.12	2.02 (0.80–5.06)
Fluoroquinolone	21 (15.7)	15 (5.8)	0.003	3.01 (1.42–6.51)
Metronidazole	14 (10.5)	16 (6.2)	0.16	1.76 (0.77–4.00)
(b) Broth microdilution test	(<i>n</i> = 73)	(<i>n</i> = 319)		
Female sex	34 (46.6)	117 (36.7)	0.14	1.51 (0.87–2.59)
Methicillin resistant isolate	48 (65.8)	142 (44.5)	0.001	2.39 (1.37–4.25)
Emergency department admission	29 (39.7)	179 (56.1)	0.01	0.52 (0.30–0.89)
Physician referral on admission	17 (23.3)	56 (17.6)	0.26	1.43 (0.72–2.71)
Healthcare-associated infection	40 (54.8)	133 (41.7)	0.04	1.70 (0.98–2.93)
Prior admission to UPHS within the preceding 30 days	12 (16.4)	74 (23.2)	0.21	0.65 (0.30–1.31)
APRDRG risk of mortality score \geq 3	55 (75.3)	218 (68.6)	0.25	1.40 (0.76–2.67)
Intravascular device	44 (60.3)	139 (43.7)	0.01	1.95 (1.13–3.41)
Malignancy	14 (19.2)	86 (27.0)	0.17	0.64 (0.32–1.24)
Receipt of any immunosuppression \leq 30 days prior to the culture date	14 (19.2)	36 (11.3)	0.07	1.87 (0.87–3.81)
ICU location on culture date	26 (35.6)	69 (21.6)	0.01	2.00 (1.11–3.57)
ICU location \leq 48 h prior to culture date	14 (19.2)	36 (11.3)	0.07	1.87 (0.87–3.81)
Inpatient antimicrobial use \leq 30 days prior to culture date*				
Any antibiotic	22 (30.1)	69 (21.6)	0.12	1.56 (0.84–2.83)
Vancomycin	10 (13.7)	28 (8.8)	0.20	1.65 (0.68–3.72)
Trimethoprim-sulfamethoxazole	3 (4.1)	5 (1.6)	0.17	2.69 (0.41–14.2)

RVS, Reduced vancomycin susceptibility; OR, odds ratio; CI, confidence interval; ICU, intensive-care unit; UPHS, University of Pennsylvania Health System; APRDRG, all patient refined-diagnosis related group.

Only those variables with a *P* value \leq 0.30 are shown.

* All other agents and classes of antimicrobials not shown due to *P* values $>$ 0.20 on univariable analyses.

data can identify the presence of RVS in the setting of bacteraemia due to *S. aureus*. Both prediction rules demonstrated good calibration and discrimination, as well as cut-off values with reasonable sensitivity and specificity and excellent negative predictive values for identifying RVS in both MSSA and MRSA isolates causing bacteraemia.

Multiple studies have demonstrated poor clinical outcomes, including increased mortality, in serious infections due to *S. aureus* with RVS as defined by

either Etest or broth microdilution testing [10–21]. As such, the ability to permit earlier identification of *S. aureus* isolates with RVS in the context of bacteraemia would have important clinical implications. The majority of clinical laboratories utilize automated systems for routine susceptibility testing to determine vancomycin MICs, and these do not accurately reflect those obtained using Etest or broth microdilution methods [23]. A simple clinical prediction rule would therefore allow for more rapid identification of RVS

Table 2. Multivariable prediction model of RVS as defined by (a) Etest and (b) broth microdilution test in *Staphylococcus aureus* bacteraemia ($n = 392$)

Variable	Regression coefficient	Adjusted OR (95% CI)	P value	Point value
(a) Etest				
Methicillin-resistant isolate	0.41	1.51 (0.97–2.34)	0.069	1
Non-white race	−0.39	0.67 (0.42–1.07)	0.096	−1
Healthcare-associated infection	−0.58	0.56 (0.32–0.96)	0.035	−1
Receipt of antimicrobial therapy ≤ 30 days prior to culture date	1.12	3.06 (1.72–5.44)	<0.001	3
(b) Broth microdilution test				
Methicillin-resistant isolate	0.90	2.45 (1.42–4.24)	0.001	1
Emergency department admission	−0.62	0.54 (0.32–0.92)	0.024	−1
Intravascular device	0.81	2.24 (1.30–3.86)	0.004	1
Malignancy	−0.67	0.51 (0.26–1.00)	0.048	−1

RVS, Reduced vancomycin susceptibility; OR, odds ratio; CI, confidence interval.

Table 3. Performance characteristics of the simplified prediction model for RVS as defined by Etest in *Staphylococcus aureus* bacteraemia

Cut-off value	Sensitivity (%)	Specificity (%)	PPV* (%)	NPV* (%)
≥ -2	100.0	0.0	34.2	n.a.
≥ -1	99.3	4.7	35.1	92.8
≥ 0	78.4	42.6	41.3	79.3
≥ 1	47.8	73.3	48.2	73.0
≥ 2	29.9	84.9	50.7	70.0
≥ 3	17.2	91.9	52.5	68.1
4	0.75	100.0	100.0	66.0

RVS, Reduced vancomycin susceptibility; PPV, positive predictive value; NPV, negative predictive value; n.a., not applicable.

* As calculated given a prevalence of RVS of 34.2%.

using readily available clinical and microbiological information. Early recognition of RVS would allow for improved risk stratification to identify patients with an increased risk of worse clinical outcomes, including greater mortality, in the context of *S. aureus* bacteraemia. This information would be an important adjunct in the overall clinical decision-making process, including early consideration of alternative therapy in patients with worsening clinical status on vancomycin, as well as more aggressive interventions such as removal of intravascular devices. For example, a recent study demonstrated improved outcomes with daptomycin compared to vancomycin treatment in patients with MRSA bacteraemia characterized by elevated vancomycin MICs [38]. Finally, given how critical the early receipt of appropriate antibiotic therapy is for improving outcomes in

serious infections, including in bacteraemia due to *S. aureus* [39, 40], awareness of a high likelihood of RVS in *S. aureus*-associated bacteraemia may aid physicians in the selection of initial empirical antimicrobial treatment.

To our knowledge, there is only one study in the literature describing a clinical prediction rule for RVS in *S. aureus* bacteraemia [22]. However, this was limited to methicillin-resistant isolates and the use of broth microdilution testing to define RVS. Interestingly, the prediction rule for RVS as defined by Etest in the present study generated a different set of predictors compared to the prediction rule using broth microdilution methods, with the exception of methicillin resistance. Previous studies have demonstrated poor correlation between the Etest and broth microdilution MIC methods, with the Etest providing

Table 4. Performance characteristics of the simplified prediction model for RVS as defined by broth microdilution test in *Staphylococcus aureus* bacteraemia

Cut-off value	Sensitivity (%)	Specificity (%)	PPV* (%)	NPV* (%)
≥ -2	100.0	0.0	18.6	n.a.
≥ -1	100.0	2.8	19.0	100.0
≥ 0	89.0	27.0	21.8	91.5
≥ 1	61.6	71.2	32.8	89.0
2	16.4	94.0	38.4	83.1

RVS, Reduced vancomycin susceptibility; PPV, positive predictive value; NPV, negative predictive value; n.a., not applicable.

* As calculated given a prevalence of RVS of 18.6%.

consistently higher MIC results [23, 25], and this probably contributed to the resulting difference in predictors in our final models. Nevertheless, many of the predictors in both models are indicators of healthcare exposure, including presence of an intravascular device, prior antimicrobial use, health-care-associated infection, and malignancy. Given that prior studies demonstrating increased mortality with RVS in *S. aureus* infections have used both Etest and broth microdilution methods to determine RVS, the availability of prediction rules utilizing either of these methods is of significant clinical utility. As such, while there is still uncertainty regarding the optimal approach for testing for RVS, we would recommend that clinicians base their selection of a prediction rule on the method used to determine vancomycin MICs at their institution, as well as defining characteristics of the patient population under treatment and availability of information.

In addition, to our knowledge, the present study is the first to derive and validate clinical prediction rules for RVS in bacteraemia due to MSSA and MRSA. While data on the impact of RVS on clinical outcomes in infections due to MSSA are limited compared to that for MRSA, currently available studies in the literature demonstrate that RVS is associated with increased mortality in bacteraemia due to methicillin-sensitive isolates [17, 20, 21]. As such, the ability to identify RVS in both MSSA and MRSA isolates causing bacteraemia will be important, particularly in the context of data suggesting increased microbial fitness of MSSA strains with RVS compared to MRSA strains with RVS [41].

Interestingly, the ORs for some predictors in both models suggested a potentially protective effect on developing *S. aureus* bacteraemia with an isolate

characterized by RVS (e.g. malignancy and non-white race). While it is possible that host and genetic factors may in part explain these findings, further research is needed to elucidate biological mechanisms that may lead to a decreased risk of infection or colonization with both MSSA and MRSA characterized by RVS.

Our clinical prediction models using broth microdilution and Etest methods demonstrated good discrimination and calibration for identifying RVS in the context of bacteraemia due to MSSA and MRSA. Furthermore, there was no significant loss of discriminatory ability in the validation cohort relative to the derivation population, therefore minimizing the possibility of overfitting and loss of reliability in samples other than our specific dataset [42]. Both integer-based prediction rules are comprised of four dichotomous predictors, thereby facilitating rapid and straightforward calculation of a total score. The prediction rules each have three demographic or clinical variables that are easily determined by clinicians, as well as the laboratory-based variable of methicillin resistance, which is often available early on during the clinical course. Finally, the selection of a particular cut-off value for the two clinical prediction rules will largely be determined by the clinical context. For example, in situations where missing and/or inappropriately treating a specific infection would be particularly detrimental (i.e. a 'rule out' situation), it will be important to ensure the use of a clinical prediction rule with a high negative predictive value (i.e. selecting the cut-off values of ≥ -1 , and ≥ -1 or ≥ 0 for RVS as determined by Etest and broth microdilution test, respectively).

Finally, there are several potential limitations of the present study. Our clinical prediction rules were derived from a cohort of patients in a single healthcare

system, and the external validity of these models needs to be evaluated before being applied to other clinical settings. Furthermore, studies demonstrating poor clinical outcomes in bacteraemia due to *S. aureus* with RVS have used a range of MIC cut-offs to determine RVS, and the utility of our clinical prediction rules are dependent on the specific Etest and broth microdilution vancomycin MIC values we used to characterize RVS. Finally, as with all similar clinical prediction rules, selection of antimicrobial therapy should ultimately depend on the specific clinical situation and judgement of the treating physicians.

In sum, we have developed and validated simple clinical prediction rules for RVS in the setting of bacteraemia due to MSSA and MRSA, and specifically using both broth microdilution and Etest methods to determine vancomycin MICs. Although host and organism factors leading to worsened clinical outcomes in RVS, as well as optimal treatment strategies for associated infections still need to be further elucidated, having an easy and rapid clinical prediction rule for early identification of RVS can be used to help guide the timely and individualized management of these serious infections.

ACKNOWLEDGEMENTS

This work was supported by the National Institutes of Health (K24 AI080942 to E.L.) and a Commonwealth Universal Research Enhancement Program grant from the Pennsylvania State Department of Health (to E.L.). The dataset on which this study was based was constructed for a prior study supported by a research grant from Cubist Pharmaceuticals (E.L.). The current study was not supported by Cubist Pharmaceuticals. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

DECLARATION OF INTEREST

E.L. has received research grant support from Merck, AstraZeneca and 3M.

REFERENCES

1. **Hidron AI, et al.** NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. *Infection Control and Hospital Epidemiology* 2008; **29**: 996–1011.
2. **Klevens RM, et al.** Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *Journal of the American Medical Association* 2007; **298**: 1763–1771.
3. **Cosgrove SE, et al.** The impact of methicillin resistance in *Staphylococcus aureus* bacteremia on patient outcomes: mortality, length of stay, and hospital charges. *Infection Control and Hospital Epidemiology* 2005; **26**: 166–174.
4. **Centers for Diseases Control and Prevention.** *Staphylococcus aureus* with reduced susceptibility to vancomycin – United States, 1997. *Morbidity and Mortality Weekly Report* 1997; **46**: 765–766.
5. **Steinkraus G, White R, Friedrich L.** Vancomycin MIC creep in non-vancomycin-intermediate *Staphylococcus aureus* (VISA), vancomycin-susceptible clinical methicillin-resistant *S. aureus* (MRSA) blood isolates from 2001–05. *Journal of Antimicrobial Chemotherapy* 2007; **60**: 788–794.
6. **Wang G, et al.** Increased vancomycin MICs for *Staphylococcus aureus* clinical isolates from a university hospital during a 5-year period. *Journal of Clinical Microbiology* 2006; **44**: 3883–3886.
7. **Hawser SP, et al.** Rising incidence of *Staphylococcus aureus* with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004–2009. *International Journal of Antimicrobial Agents* 2011; **37**: 219–224.
8. **Etest technical manual.** AB Biodisk (http://www.abbiobisk.com/bd_litt_etm.html). Accessed 5 November 2011.
9. **Clinical and Laboratory Standards Institute.** Methods for dilutional antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Wayne, PA: CLSI, 2007.
10. **Hidayat LK, et al.** High-dose vancomycin therapy for methicillin-resistant *Staphylococcus aureus* infections: efficacy and toxicity. *Archives of Internal Medicine* 2006; **166**: 2138–2144.
11. **Sakoulas G, et al.** Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *Journal of Clinical Microbiology* 2004; **42**: 2398–2402.
12. **Moise PA, et al.** Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrobial Agents and Chemotherapy* 2007; **51**: 2582–2586.
13. **Moise-Broder PA, et al.** Accessory gene regulator group II polymorphism in methicillin-resistant *Staphylococcus aureus* is predictive of failure of vancomycin therapy. *Clinical Infectious Diseases* 2004; **38**: 1700–1705.
14. **Soriano A, et al.** Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *Clinical Infectious Diseases* 2008; **46**: 193–200.

15. **Lodise TP, et al.** Relationship between vancomycin MIC and failure among patients with methicillin-resistant *Staphylococcus aureus* bacteremia treated with vancomycin. *Antimicrobial Agents and Chemotherapy* 2008; **52**: 3315–3320.
16. **Wang JL, et al.** Nosocomial methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia in Taiwan: Mortality analyses and the impact of vancomycin, MIC=2 mg/l, by the broth microdilution method. *BMC Infectious Diseases* 2010; **10**: 159.
17. **Aguado JM, et al.** High vancomycin MIC and complicated methicillin-susceptible *Staphylococcus aureus* bacteremia. *Emerging Infectious Diseases* 2011. (<http://www.cdc.gov/EID/content/17/6/1099.htm>). Accessed 9 May 2011.
18. **Yoon YK, et al.** Predictors of persistent methicillin-resistant *Staphylococcus aureus* bacteraemia in patients treated with vancomycin. *Journal of Antimicrobial Chemotherapy* 2010; **65**: 1015–1018.
19. **Kullar R, et al.** Impact of vancomycin exposure on outcomes in patients with methicillin-resistant *Staphylococcus aureus* bacteremia: support for consensus guidelines suggested targets. *Clinical Infectious Diseases* 2011; **52**: 975–981.
20. **Holmes NE, et al.** Antibiotic choice may not explain poorer outcomes in patients with *Staphylococcus aureus* bacteremia and high vancomycin minimum inhibitory concentrations. *Journal of Infectious Diseases* 2011; **204**: 340–347.
21. **Price J, et al.** Paradoxical relationship between the clinical outcome of *Staphylococcus aureus* bacteremia and the minimum inhibitory concentration of vancomycin. *Clinical Infectious Diseases* 2009; **48**: 997–998.
22. **Lubin AS, et al.** Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant *Staphylococcus aureus* bloodstream infections. *Clinical Infectious Diseases* 2011; **52**: 997–1002.
23. **Hsu DI, et al.** Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant *Staphylococcus aureus* (MRSA) infections. *International Journal of Antimicrobial Agents* 2008; **32**: 78–85.
24. **Sader HS, Rhomberg PR, Jones RN.** Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* 2009; **53**: 3162–3165.
25. **Vaudaux P, et al.** Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* 2010; **54**: 3861–3870.
26. **Clinical and Laboratory Standards Institute.** Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S18. Wayne, PA, CLSI, 2008.
27. **Clinical and Laboratory Standards Institute.** Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A9. Wayne, PA, CLSI, 2006.
28. **Barton TD, et al.** High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. *Infection Control and Hospital Epidemiology* 2005; **26**: 93–99.
29. **Gasink LB, et al.** Fluoroquinolone-resistant *Pseudomonas aeruginosa*: assessment of risk factors and clinical impact. *American Journal of Medicine* 2006; **119**: e19–e25.
30. **Lee I, et al.** Risk factors for fluconazole-resistant *Candida glabrata* bloodstream infections. *Archives of Internal Medicine* 2009; **169**: 379–383.
31. **Quan H, et al.** Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Medical Care* 2005; **43**: 1130–1139.
32. **Mickey RM, Greenland S.** The impact of confounder selection criteria on effect estimation. *American Journal of Epidemiology* 1989; **129**: 125–137.
33. **Hosmer DW, Lemeshow S.** *Applied Logistic Regression*. New York, NY: John Wiley & Sons, 1989.
34. **Harrell Jr. FE, Lee KL, Mark DB.** Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Statistical Medicine* 1996; **15**: 361–387.
35. **Efron B, Tibshirani RJ.** *An Introduction to the Bootstrap*. New York, NY: Chapman & Hall, 1998.
36. **Steyerberg EW, et al.** Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. *Journal of Clinical Epidemiology* 2001; **54**: 774–781.
37. **Anthony K, et al.** Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant *Staphylococcus aureus* bacteremia. *Infection Control and Hospital Epidemiology* 2012; **33**: 160–166.
38. **Moore CL, et al.** Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant *Staphylococcus aureus* with a high vancomycin minimum inhibitory concentration: a case-control study. *Clinical Infectious Diseases* 2012; **54**: 51–58.
39. **Lodise TP, et al.** Outcomes analysis of delayed antibiotic treatment for hospital-acquired *Staphylococcus aureus* bacteremia. *Clinical Infectious Diseases* 2003; **36**: 1418–1423.
40. **Paul M, et al.** Importance of appropriate empirical antibiotic therapy for methicillin-resistant *Staphylococcus aureus* bacteraemia. *Journal of Antimicrobial Chemotherapy* 2010; **65**: 2658–2665.
41. **Ender M, et al.** Fitness cost of SCCmec and methicillin resistance levels in *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* 2004; **48**: 2295–2297.
42. **Harrell FE.** *Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis*. New York: Springer, 2001.